hepatitis b resistance in iran

emerging new medications in the treatment of hbv produces hope and promises for curing of hbv. over the past decade, the development of oral nucleoside/nucleotide analogs (nas) with favorable potencies and tolerabilities has led to substantial advances in chronic hepatitis b (chb) therapy. the oral anti-hbv agents currently approved are lamivudine, adefovir dipivoxil , entecavir , telbivudine, clevudine, and tenofovir. treatment algorithms have been developed to assist in identification of suitable candidates for treatment and to determine and initiate appropriate treatment . in this review the problem of drug resistance in the course of chronic hepatitis b treatment are discussed in detail from both aspects of clinical and genetics.